Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp WT (NQ: LEXXW ) 0.9400 -0.1000 (-9.62%) Streaming Delayed Price Updated: 3:50 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 51,663 Open 0.7900 Bid (Size) 0.7400 (4) Ask (Size) 1.170 (100) Prev. Close 1.040 Today's Range 0.7231 - 1.010 52wk Range 0.0500 - 2.500 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 September 27, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO September 06, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Performance YTD +88.00% +88.00% 1 Month -27.13% -27.13% 3 Month +16.58% +16.58% 6 Month -43.37% -43.37% 1 Year +347.62% +347.62% More News Read More Lexaria Releases Strategic Letter from the Outgoing CEO September 05, 2024 Via ACCESSWIRE Lexaria Welcomes Industry Veteran as New CEO September 05, 2024 Via ACCESSWIRE Lexaria Enters a Material Transfer Agreement for DehydraTECH Research September 03, 2024 Via ACCESSWIRE Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules August 29, 2024 Via ACCESSWIRE First Results from Lexaria's Second GLP-1 Human Pilot Study August 27, 2024 Via ACCESSWIRE Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study August 22, 2024 Via ACCESSWIRE Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study August 21, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’ August 27, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study August 22, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study August 19, 2024 Via CannabisNewsWire Topics Regulatory Compliance Exposures Legal Regulatory Positive Results from Lexaria's Molecular Characterization Study August 19, 2024 Via ACCESSWIRE Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study July 17, 2024 Via ACCESSWIRE Lexaria Preparing For Strategic Growth July 16, 2024 Via ACCESSWIRE Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study July 09, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study July 17, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy July 08, 2024 Via ACCESSWIRE Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study June 18, 2024 Via ACCESSWIRE Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study June 05, 2024 Via ACCESSWIRE CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study May 23, 2024 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Awards Contract For Third GLP-1 Human Pilot Study May 23, 2024 Via ACCESSWIRE Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy May 21, 2024 Via ACCESSWIRE Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study May 17, 2024 Via ACCESSWIRE Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study May 08, 2024 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
